| Not Yet Recruiting | Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A NCT06136507 | Jiangsu Gensciences lnc. | Phase 3 |
| Not Yet Recruiting | Post Approval Observational Study to Learn More About How Safe Octocog Alfa is and How Well it Works in Patien NCT07446010 | Bayer | — |
| Enrolling By Invitation | Palliative Care Needs of Children With Rare Diseases and Their Families NCT06938542 | Children's National Research Institute | N/A |
| Recruiting | A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemo NCT06703606 | Pfizer | Phase 1 |
| Recruiting | Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein NCT06142552 | Jiangsu Gensciences lnc. | Phase 3 |
| Recruiting | Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study NCT05935358 | Octapharma | Phase 4 |
| Terminated | Bone Microarchitecture in Men With Hemophilia NCT05127681 | Hospices Civils de Lyon | N/A |
| Completed | rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study NCT06137092 | AryoGen Pharmed Co. | Phase 3 |
| Recruiting | Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab NCT05802836 | Christoph Königs | — |
| Active Not Recruiting | A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moder NCT05181618 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection NCT05265286 | Jiangsu Gensciences lnc. | Phase 2 |
| Completed | A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor V NCT04864743 | Jiangsu Gensciences lnc. | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in NCT04431726 | Hoffmann-La Roche | Phase 3 |
| Withdrawn | Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform NCT02196207 | Margaret Ragni | Phase 3 |
| Terminated | Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A NCT04046848 | Octapharma | Phase 1 / Phase 2 |
| Completed | Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients Wit NCT03376516 | Octapharma | Phase 3 |
| Completed | Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A NCT02954575 | Octapharma | Phase 3 |
| Completed | Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale NCT02502149 | Bioverativ Therapeutics Inc. | Phase 3 |
| Completed | An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A NCT02172950 | CSL Behring | Phase 3 |
| Completed | Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII NCT01992549 | Octapharma | Phase 3 |
| Completed | Pharmacokinetics of rFVIIIFc at Two Vial Strengths NCT02083965 | Bioverativ Therapeutics Inc. | Phase 1 |
| Completed | Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients NCT01712438 | Octapharma | Phase 3 |
| Terminated | Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A NCT01405742 | University of Pittsburgh | Phase 3 |
| Completed | Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTP NCT01341912 | Octapharma | Phase 3 |
| Completed | Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVI NCT01181128 | Bioverativ Therapeutics Inc. | Phase 3 |
| Completed | Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A NCT01125813 | Octapharma | Phase 3 |
| Completed | Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A NCT01027377 | Bioverativ Therapeutics Inc. | Phase 1 |
| Completed | Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienc NCT01051076 | City of Hope Medical Center | N/A |
| Withdrawn | Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of F NCT01051544 | City of Hope Medical Center | N/A |
| Completed | Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A NCT00323856 | Grifols Biologicals, LLC | Phase 4 |
| Completed | Canadian Hemophilia Prophylaxis Study NCT01085344 | The Hospital for Sick Children | Phase 4 |